Skip to main content
Contact Us
Subscribe
E-Edition
84°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Argenx Se ADR
(NQ:
ARGX
)
460.32
-11.00 (-2.33%)
Streaming Delayed Price
Updated: 3:24 PM EDT, Jul 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Argenx Se ADR
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
AstraZeneca Seeks Expanded Use For Soliris As First Targeted Therapy For Pediatric Patients With Autoimmune Neuromuscular Disease
June 26, 2023
The European Union has reco
Via
Benzinga
Argenx's Vyvgart Hytrulo Becomes First FDA Approved Subcutaneous Option For Generalized Myasthenia Gravis
June 21, 2023
The FDA has approved Argenx SE's (NASDAQ: ARGX) Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), an injection for subcutaneous (SC) use for generalized myasthenia gravis (gMG) in adult...
Via
Benzinga
argenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Generalized Myasthenia Gravis
June 20, 2023
From
argenx SE
Via
GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
June 20, 2023
Via
Benzinga
The Latest Analyst Ratings for argenx
June 07, 2023
Via
Benzinga
Analyst Expectations for argenx's Future
June 07, 2023
Via
Benzinga
Expert Ratings for argenx
May 31, 2023
Via
Benzinga
Analyst Ratings for argenx
April 21, 2023
Via
Benzinga
A Bearish Sign Appears On argenx's Chart
March 23, 2023
Via
Benzinga
argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy
June 20, 2023
From
argenx SE
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For May 31, 2023
May 31, 2023
Via
Benzinga
argenx to Present at Upcoming Investor Conferences
May 31, 2023
From
argenx SE
Via
GlobeNewswire
Booking Holdings To Rally Around 18%? Here Are 10 Other Analyst Forecasts For Friday
May 05, 2023
Wells Fargo raised the price target for Royal Caribbean Cruises Ltd. (NYSE: RCL) from $78 to $88. Wells Fargo analyst Daniel Politzer maintained an Overweight rating. Royal Caribbean Cruises shares...
Via
Benzinga
Analyst Ratings for argenx
March 20, 2023
Via
Benzinga
Analyst Boosts Immunovant Price Target After Updated Pipeline Realignment
March 20, 2023
Via
Benzinga
argenx Reports First Quarter 2023 Financial Results and Provides Business Update
May 04, 2023
From
argenx SE
Via
GlobeNewswire
argenx announces results of Annual General Meeting of Shareholders
May 03, 2023
From
argenx SE
Via
GlobeNewswire
argenx to Present at BofA Securities 2023 Health Care Conference
May 02, 2023
From
argenx SE
Via
GlobeNewswire
argenx to Report First Quarter 2023 Financial Results and Business Update on May 4, 2023
April 27, 2023
From
argenx SE
Via
GlobeNewswire
5 Analysts Have This to Say About argenx
March 03, 2023
Via
Benzinga
Earnings Outlook For argenx
March 01, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2023
April 25, 2023
Via
Benzinga
7 Biotech Stocks That Could Cure Your Portfolio Woes
April 19, 2023
If you want to revitalize your portfolio with some exciting opportunities, these biotech stocks to buy might fit the bill.
Via
InvestorPlace
argenx Demonstrates Commitment to Redefining Treatment Goals for Generalized Myasthenia Gravis with Multiple Presentations at American Academy of Neurology 2023 Annual Meeting
April 18, 2023
From
argenx SE
Via
GlobeNewswire
argenx and Genmab Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
April 17, 2023
From
argenx SE
Via
GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
April 12, 2023
Via
Benzinga
argenx Announces Annual General Meeting of Shareholders on May 2, 2023
March 17, 2023
From
argenx SE
Via
GlobeNewswire
argenx Announces UK MHRA Approval of VYVGART for the Treatment of Generalized Myasthenia Gravis
March 15, 2023
From
argenx SE
Via
GlobeNewswire
argenx Reports Full Year 2022 Financial Results and Provides Fourth Quarter Business Update
March 02, 2023
From
argenx SE
Via
GlobeNewswire
argenx Announces Planned Transition of Chief Operating Officer
March 02, 2023
From
argenx SE
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.